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Immunocompromised patients are at risk of developing toxoplasmosis, and although chemotherapy is
available, standard treatments are often complicated by severe side effects. Artemisinin is a new highly potent
antimalarial drug that has activity against Toxoplasma gondii in vitro. However, artemisinin derivatives have
previously been ineffective in vivo using a rat model of toxoplasmosis. In the present study, the efficacy of
several new artemisinin derivates was investigated for treatment of mice infected with the parasite Toxoplasma
gondii. Artemiside and artemisone displayed better inhibition than either artemisinin or artesunate against the
parasite in vitro. Artemiside and artemisone treatment controlled parasite replication in vivo, and mice
survived the acute infection. In a murine model of reactivated toxoplasmosis, both drugs increased survival,
although artemiside was more effective. These results indicate that these newer derivatives of artemisinin may
have potential for treatment of toxoplasmosis.
The protozoan parasite Toxoplasma gondii infects a large
number of warm-blooded animals and is estimated to chroni-
cally infect up to one-third of the world’s human population
(11). The life cycle includes a sexual phase in the intestine of
cats, leading to fecal shedding of a spore-like stage known as
the oocyst (9). Asexual development takes place in a wide
range of warm-blooded vertebrates and is characterized by an
acute phase, during which the parasite propagates rapidly as
tachyzoites, and a chronic phase, typified by tissue cysts con-
taining slow-growing forms called bradyzoites (9). Humans can
become infected by ingestion of oocysts that contaminate wa-
ter or tissue cysts in undercooked meat. Following oral uptake,
the parasite crosses the gut epithelium and disseminates
throughout the body (5). The acute phase generally produces
only mild symptoms in immunocompetent adults and is readily
controlled by the immune response (29). The latent stage of
infection is characterized by the presence of parasites within
tissue cysts that form in the skeletal muscle and central nervous
system (25).
Toxoplasmosis is of concern during pregnancy, due to the
ability of the parasite to cross the placental barrier and cause
infection in the developing fetus (21, 41). Additionally, immu-
nocompromised patients are predisposed to development of
reactivated toxoplasmosis due to cyst rupture and uncontrolled
proliferation of tachyzoites (25). Patients at risk include those
with underlying conditions, such as AIDS, or individuals who
are therapeutically immunosuppressed due to organ transplan-
tation or cancer chemotherapy. Toxoplasmic encephalitis is the
most common clinical manifestation of reactivated disease in
AIDS patients who do not receive highly active antiretroviral
therapy or antiparasitic prophylaxis (25). If left untreated, re-
activation leads to severe central nervous system (CNS) com-
plications and may result in death.
Standard therapy for toxoplasmosis in humans includes com-
binations of pyrimethamine plus sulfadiazine. However, these
drugs often cannot be tolerated due to severe side effects (22).
Further, the current treatments control only actively prolifer-
ating parasites but have limited activity against bradyzoites
within tissue cysts and hence do not eliminate the chronic
infection; thus, prolonged treatment is necessary for immuno-
compromised patients (22). Atovaquone, originally developed
for malaria, is also active against T. gondii both in vitro and in
vivo, and it has been reported to have some activity against
tissue cysts when administered for long periods of time (2).
Atovaquone in combination with pyrimethamine or sulfadia-
zine was reported to prevent relapse of toxoplasmosis in AIDS
patients (7). However, it has also been associated with break-
through failures in other cases (4, 24). Hence, there is a need
for the development of new therapeutics for treatment of toxo-
plasmosis.
Artemisinin (Fig. 1) is a sesquiterpene lactone produced by
the plant Artemisia annua and is used for the treatment of
fevers and chills as part of traditional Chinese herbal medicine
(14). Artemisinin and its derivatives, including artesunate (Fig.
1), dihydroartemisinin (DHA), and artemether, are potent and
rapidly acting antimalarial drugs that are currently used widely
in combination therapies to treat malaria (3). The new arte-
misinin derivatives artemisone and artemiside, the thiomor-
pholine precursor of artemisone, have markedly superior in
vitro antimalarial activity against chloroquine-sensitive and
-resistant Plasmodium falciparum lines and also display greater
activities against the rodent malaria Plasmodium berghei in vivo
(40). The enhanced efficacy of artemisone is also apparent in
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studies involving an Aotus monkey model for P. falciparum
malaria (13). Artemisone has greatly reduced neurotoxicity
compared to the major circulating metabolite of artesunate,
namely DHA, and as such it has a superior pharmacokinetic
profile for humans (28).
The parent compound artemisinin is effective against T. gon-
dii, although the 50% effective concentrations (EC50s) are
50-fold higher than those reported for P. falciparum (27).
The mechanism of action of artemisinin and its derivatives is
dependent upon the presence of the endoperoxide bridge (14),
although the difference in potencies between P. falciparum and
T. gondii suggests that different targets may be affected in these
two organisms. The derivatives artesunate, artemether, and
artemisone (27), as well as several other new derivatives (17),
have also been shown to be more potent against T. gondii in
vitro. Despite in vitro activity, previous studies tested arte-
mether with a rat model with concurrent infection with Pneu-
mocystis carinii and T. gondii and found that it was ineffective
in controlling infection (6).
In the present study, we tested the antiparasitic efficacy of
several new derivates of artemisinin against T. gondii cultured
in vitro and in murine models of acute and reactivated toxo-
plasmosis.
MATERIALS AND METHODS
Parasite growth assay. The T. gondii strain RH (ATCC 50838), clone 2F
(ATCC 50839), which expresses bacterial -galactosidase, was used for in vitro
growth assays (27). Parasites were maintained as tachyzoites in human foreskin
fibroblast cells grown in Dulbecco’s modified Eagle’s medium with 10 mM
HEPES, 44 mM sodium bicarbonate, 10% fetal bovine serum, 2 mM glutamine,
and 10 g/ml gentamicin. For growth inhibition assays, parasites were inoculated
in 96-well plates containing monolayers of human foreskin fibroblast cells and
were treated with different compounds at concentrations ranging from 0.010 M
to 1.0 M for 72 h at 37°C. Following treatment, the culture medium was
removed, and parasite growth was determined based on detection of -galacto-
sidase activity, as described previously (27). The end product of the reaction was
read as absorbance at 570 nm, and mean values from three independent exper-
iments were used to estimate the EC50s and EC90s by curve fitting using non-
linear regression with a variable slope in Prism 5.0 (GraphPad Software Inc.).
Mouse infections. The luciferase expressing the PRU-Luc-GFP type II strain
(kindly provided by J. Boothroyd, Stanford University School of Medicine, CA)
of T. gondii was used for mouse infections. CD1 outbred female mice (Charles
River Laboratories, Wilmington, MA) 8 to 10 weeks of age were used for all
acute infection studies. CD1 mice are relatively resistant to infection by type II
strains, so we first established the dose of tachyzoites that would cause lethal
infection in a majority of mice (data not shown). Control and drug-treated mice
were infected by intraperitoneal (i.p.) injection of 106 tachyzoites in 0.2 ml
phosphate-buffered saline, compounds were injected (subcutaneously [s.c.] 10
mg/kg) every day for 8 days, and survival was followed for 25 days. Animals were
maintained in an AAALAC-approved facility overseen by the Institutional An-
imal Care Committee at Washington University.
Parasite burdens. For bioluminescence experiments, animals were imaged at
2-day intervals, following treatment with mild anesthesia using isofluorene and
i.p. injection of 0.15 mg/kg body weight of firefly luciferin D (Biosynth AG, Staad,
Switzerland). Animals were imaged using a Xenogen IVIS 100 (Caliper Life-
Sciences, Hopkinton, MA), and data are expressed in relative light units. As
described previously, the output from luciferase imaging in vivo is not directly
related to parasite numbers but rather provides a relative index of the severity of
infection (30). Experiments contained three animals per group that were mon-
itored for 25 days postinfection, after which chronic infections were confirmed by
examining homogenates of the brain for tissue cysts. Briefly, animals were hu-
manely sacrificed, and the brains were removed and homogenized in 1.0 ml of
sterile phosphate-buffered saline, pH 7.2. Homogenates were examined by
bright-field or phase-contrast microscopy at 40 magnification, cysts were
counted from four separate 20-l aliquots, and counts were used to estimate the
total number of cysts per brain.
FIG. 1. Structure diagrams of artemisinin and related compounds. Artemisinin, 1; artesunate, 2; DHA, 3; artemether, 4; artemisone, 5;
artemiside, 6; sulfamide derivative, 7; benzylpiperazine derivative, 8; pyrimidylpiperazine derivative, 9; and 4-fluorophenyl derivative, 10.
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Murine model of reactivated toxoplasmosis. Inbred female gamma interferon
(IFN-/) mice on a C57BL/6 background were maintained under specific
pathogen-free conditions. Eight- to 10-week-old mice were orally infected with
20 tissue cysts of PRU-Luc-GFP T. gondii that were obtained from the brains of
chronically infected wild-type mice. C57BL/6 mice are highly susceptible to
infection and develop high tissue cyst burdens in the chronic phase (37). To
control acute infection, mice were treated with sulfadiazine (Sigma-Aldrich, St.
Louis, MO) in the drinking water (400 mg/liter) for 3 weeks beginning 2 days
after infection. Two days after discontinuation of sulfadiazine, mice were treated
s.c. with compounds (10.0 mg/kg [body weight]) every day for 8 days. Survival and
parasite burdens were monitored at 2-day intervals for 25 days, as described
above.
Compounds. Structures of compounds used in this study are given in Fig. 1.
Artemisinin was obtained from Sigma Aldrich. Artesunate was a gift from Knoll
AG, Basel, Switzerland. The 10-amino-artemisinins artemisone, artemiside, the
sulfamide derivative, the benzylpiperazine derivative, and the pyrimidylpipera-
zine derivative were prepared as previously described (10). The 4-fluorophenyl
derivative was prepared as described previously (12). Compounds were dissolved
in dimethyl sulfoxide (DMSO) and stored at 80°C in single-use aliquots until
used for in vitro studies. Alternatively, compounds were dissolved in DMSO and
stored at 4°C for in vivo studies.
RESULTS
Testing the in vitro antiparasitic activity of new artemisinin
derivates. The antiparasitic activities of several new artemisi-
nin derivates were monitored using a -galactosidase assay for
parasite growth in vitro (27). This assay relates enzyme activity
from a transgenic T. gondii line expressing Escherichia coli
-galactosidase to parasite numbers and is highly linear over a
wide range of cell numbers (33). We used a derivative of the
RH strain for these experiments, as it represents the rapidly
growing type I strains that are acutely virulent in the mouse
model. Following treatment in vitro for 72 h, all of the com-
pounds inhibited parasite growth, with similar EC50s ranging
from 0.11 to 0.21 M and with EC50s ranging from 0.17 to
0.37 M (Fig. 2; Table 1). These activities compare favorably
to those of artemisinin, which previous studies have indicated
has an EC50 in vitro of 0.8 M (27). The most potent com-
pounds were artemiside and artemisone (Fig. 2; Table 1). Ar-
temisone was somewhat less potent than previously reported
(EC50 of 0.03 M) (27), although further testing of these
earlier stocks reveal inhibition consistent with that reported
here (data not shown). This loss of potency may have resulted
from freezing the stocks in DMSO and thawing prior to testing,
a procedure we subsequently determined resulted in modest
loss of activity. None of the compounds demonstrated overt
toxicity to host cell monolayers (data not shown).
Effect of artemisinin derivates on acute infection with T.
gondii in the murine model. We tested the antimicrobial activ-
ity of the most-active compounds using an in vivo assay for
acute toxoplasmosis in the mouse. Mice were infected i.p. with
tachyzoites of type II (PRU-Luc-GFP) T. gondii, compounds
were injected every day for 8 days, and survival was monitored.
While all control mice and most artemisinin-treated mice suc-
cumbed to infection, 60% of the artemiside-treated mice and
more than 50% of the artemisone-treated mice survived the
infection (Fig. 3A). To follow parasite replication, mice were
infected as described above, and parasite numbers were de-
tected by bioluminescence imaging. All control mice and the
majority of artemisinin-treated mice developed high parasite
numbers and died due to the uncontrolled infection (Fig. 2B).
Artemiside- and artemisone-treated mice were able to control
parasite replication and survived, indicating that these com-
pounds effectively blocked replication and/or resulted in killing
of parasites in vivo (Fig. 3B). To evaluate cyst formation in the
chronic phase of the infection, brains were removed from
chronically infected mice at 25 days postinfection, and cysts
were counted microscopically. Artemiside- and artemisone-
treated mice developed significantly lower cyst numbers in the
brain compared to artemisinin-treated mice, confirming the
antiparasitic efficacy of the compounds (Fig. 3C). This result
likely reflects lower burdens of tachyzoites that developed in
treated animals, rather than a direct effect on tissue cysts.
Although cyst counts were not available from control mice,
which succumbed to infection, separate studies using sublethal
doses (about 10-fold lower than those used here) resulted in
cyst burdens that ranged from 200 to 300 cysts per brain (data
not shown).
Effect of artemisinin derivates on reactivation of latent T.
gondii infection. To simulate reactivation of latent infection,
we used the murine model of reactivated toxoplasmosis in
IFN-/ mice, similar to that described previously (38). IFN-
/ mice are highly susceptible to both acute (39) and chronic
TABLE 1. Effective concentrations for inhibition of T. gondii
growth in vitrob




Sulfamide derivative 0.158 0.235
4-Fluorophenyl derivative 0.182 0.271
Benzylpiperazine derivative 0.213 0.339
Pyrimidylpiperazine derivative 0.156 0.263
a Compounds correspond to the respective structures shown in Fig. 1.
b Data estimated from curve fitting shown in Fig. 2, based on nonlinear re-
gression, least-squares fit, and a variable Hill slope.
FIG. 2. Inhibition of in vitro growth of T. gondii by artemisinin
derivatives. Parasite growth was monitored by measurement of -ga-
lactosidase activity (absorbance at 570 nm) following 72 h of incuba-
tion with the different compounds (see Materials and Methods). Ar-
temiside and artemisone showed slightly better activity in vitro
compared to the other compounds. 7, sulfamide derivative; 8, ben-
zylpiperazine derivative; 9, pyrimidylpiperazine derivative; and 10, 4-
fluorophenyl derivative.
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reactivation (36) of toxoplasmosis. In order to test the efficacy
of compounds during reaction, mice were challenged with par-
asites and treated with sulfadiazine to suppress acute infection
and allow development of tissue cysts, which occurs during the
first few weeks (Fig. 4A). Treatment was then removed to
allow reactivation, which occurs by a process of stage conver-
sion from bradyzoite to tachyzoite. Because IFN-/ mice
cannot control proliferation of tachyzoites, they rapidly suc-
cumb to infection following removal of sulfadiazine. We com-
pared the efficacy of the most potent artemisinin derivatives
using this in vivo model. Following the removal of sulfadiazine,
treatment with artemiside prolonged survival in 80% of the
mice, while treatment with artemisone prolonged survival in
60% of mice (Fig. 4B). In contrast, all of the control mice died
within 10 days (Fig. 4B). Although these two compounds were
able to control the initial phases of reactivated infection, they
did not result in a complete cure. Rather, when the drugs were
discontinued, mice began dying at day 18, and all mice even-
tually died by day 25 (data not shown). This result indicates
that artemisinin compounds were not able to eradicate the
chronic infection, and hence, they likely do not act on brady-
zoites directly. Similar outcomes are seen with treatment with
other drugs that are nonetheless capable of controlling repli-
cation of tachyzoites, such as atovaquone, which has previously
been tested using a similar model (10, 32).
DISCUSSION
Previous studies have shown that although artemisinin is
somewhat active against T. gondii in vitro, it requires near-
micromolar levels to inhibit in vitro growth by 50% (EC50 is 0.8
M) (27). Several artemisinin derivatives, including arte-
mether, artesunate, and artemisone, have been shown to be
more effective against T. gondii in vitro (27). In comparison,
artemisinin derivatives tested here demonstrate that artemi-
sone and artemiside are the most potent analogs to date in
FIG. 3. Inhibition of in vivo growth of T. gondii by artemisinin
derivatives. (A) Survival of mice following oral challenge with T. gondii
and administration of artemisinin derivates. CD1 mice were infected
i.p. with 106 tachyzoites of type II (PRU-Luc-GFP) T. gondii, and
compounds were injected (s.c. with 10 mg/kg) every day for 8 days.
Survival of mice was monitored for 25 days. The majority of the
artemiside- and artemisone-treated mice survived the infection, while
artemisinin-treated and control mice died. Combined results from the
three experiments, n 	 3 or 4 animals per group, are shown. (B) Par-
asite burdens in mice during acute infection as measured by luciferase
imaging. CD1 mice were infected with 106 tachyzoites of type II (PRU-
Luc-GFP) parasites, treated with compounds (10 mg/kg s.c.) every day
for 8 days, and imaged every second day. Artemiside- and artemisone-
treated mice were able to control the infection. Experiments were
repeated four times; n 	 3 or 4 animals per group. Graph shows one
representative experiment. † indicates 4 of 5 animals succumbed to
infection; thus, the average luciferase (Luc) value dropped after this
point. †† indicates all animals succumbed to infection. Luc values
represent relative light output. (C) Chronic infection in mice as mon-
itored by cyst formation in the brains of CD1 mice. Artemiside- and
artemisone-treated mice developed lower cyst numbers in the brain
compared to artemisinin-treated mice. Data shown here are combined
results from three experiments; n 	 2 animals per group. Numbers
represent an estimate of the total number of cysts per brain. Numbers
are not available for control mice, which succumbed to infection (†).
FIG. 4. Inhibition of reactivation of chronic toxoplasmosis by arte-
misinin derivatives. (A) Murine model of reactivated toxoplasmosis. At
day 0, IFN-/ mice were infected orally with 20 cysts of PRU-Luc-
GFP, and 2 days later sulfadiazine (400 mg/kg) was administered for 3
weeks in the drinking water. Two days after discontinuation of the
drug, compounds were administered for 8 days (s.c., 10 mg/kg), and
survival was monitored. (B) Treatment with artemiside or artemisone
resulted in increased survival following reactivation. Data shown are
combined results from three individual experiments; n	 3 to 5 animals
per group.
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terms of inhibiting growth of T. gondii in vitro. We tested these
derivatives only against the rapidly growing type I strain RH,
and it is conceivable that they might have different potencies
against slower-growing type II strains, which account for most
human infections (1, 15). Moreover, the efficacy of artemisi-
nins against more diverse strains of T. gondii, which have re-
cently been recognized as common in regions such as South
America (18, 20), remains to be established. Nonetheless, our
studies demonstrate that several artemisinin derivatives show
promise for inhibiting T. gondii in vitro and in vivo.
Artemisone is a 10-alkylaminoartemisinin that was devel-
oped as a potent antimalarial drug (13). It demonstrated ex-
cellent pharmacodynamics and pharmacokinetics, and it was
well tolerated by subjects in phase I trials (28). Artemisone
displayed greater efficacy than artesunate (approximately
threefold) in phase II trials with nonsevere-malaria patients
(19). Artemisone also possesses negligible neurotoxicity both
in vitro and in vivo (28). In contrast, the neurotoxicity of the
current clinically used derivatives of artemisinins, such as ar-
tesunate or DHA, present a concern if protracted dose load-
ings are to be used against targets other than malaria. Al-
though artemisinin and its derivatives are partially effective in
inhibiting T. gondii in vitro, few studies have been performed to
evaluate in vivo efficacies. A previous study using artemether,
an analogue that has slightly lower activity in vitro, failed to
show efficacy in a rat model of combined infection with T.
gondii and P. carinii (6). This study used relatively high doses of
compounds (18 and 100 mg/kg), and the failure to observe
antitoxoplasmal activity may relate to characteristics of the rat
model, a host that is highly resistant to toxoplasmosis. Here, we
chose to explore the activities of several artemisinin derivatives
in more susceptible murine models for acute and chronic toxo-
plasmosis.
We have previously found that the more lipophilic amino-
artemisinin derivatives tend to be more active as antimalarial
drugs in vitro. This correlation is also seen in vivo, where more
lipophilic compounds, such as artemiside, exhibit at least
threefold greater activity against both chloroquine-sensitive
and -resistant strains of P. berghei and Plasmodium yoelii (10).
To be effective in treating reactivation of chronic toxoplasmo-
sis, compounds need to penetrate the blood-brain barrier.
Therefore, we have selected compounds with a range of li-
pophilicities in order to establish how important this is in
relation to in vivo activities. The log P values (log10 of the
partition coefficient) for selected compounds are given in Fig.
1 and reflect their relative hydrophobicity as previously deter-
mined (10). However, it is clear from the in vitro data shown in
Fig. 2 that there is no simple relationship between lipophilicity
and efficacy. Rather, the studies demonstrate that artemisone
(log P 	 2.49) and artemiside (log P 	 4.97) are the most
active of the compounds. We observed that artemiside and
artemisone were approximately equipotent and were about
eightfold more effective than artemisinin and about twofold
more active than artesunate. They were also slightly better
than a series of semisynthetic alkylated derivatives of artemisi-
nin that have been further described elsewhere (13). Other
reports comparing artemisinin and artemether and several syn-
thetic analogues report much higher EC50s (i.e., 8 uM for
artemisinin [17] versus 0.8 uM for our studies [27]); although
the reasons for this discrepancy are unknown.
Based on their in vitro efficacy and favorable pharmacoki-
netic and pharmacodynamic properties, we tested artemisone
and artemiside using in vivo models for toxoplasmosis. Both of
these compounds were effective in reducing mortality during
acute challenge in the mouse model. Furthermore, there was
an accompanying reduction in the chronic burden of tissue
cysts in the CNS. Our studies do not suggest that either com-
pound acts directly on bradyzoites within tissue cysts. Rather,
the protective outcome is likely due to the overall reduced
parasite burden due to inhibition and/or killing of tachyzoites
in vivo. Although the doses of compounds necessary to achieve
this effect are quite high, this may reflect pharmacokinetic
parameters of the murine model (i.e., more-rapid turnover
and/or clearance). Hence, the effective concentrations used
here cannot be directly extrapolated to other hosts, including
humans.
Although current antibiotic therapy is available for toxoplas-
mosis, it suffers from problems of intolerance to sulfa drugs
combined with a requirement for long-term maintenance, ow-
ing to a lack of efficacy against bradyzoites within tissue cysts
(22). Although artemisinin derivatives do not directly address
this deficiency, they may offer some potential for extending the
spectrum of therapies available for toxoplasmosis. The ability
to control tachyzoite replication may have utility for treatment
of either primary acute toxoplasmosis or reactivation of
chronic infection. Ocular toxoplasmosis is generally recognized
to result from reactivation of congenital infection, yet in some
regions, notably southern Brazil, ocular infections can occur
following newly acquired infections in immunocompetent
adults (16, 34). Ocular infections are often severe in these
regions, thus representing patient populations for which new
therapies with reduced toxicity and fewer side effects may be
particularly valuable.
New drugs capable of controlling acute replication would
also be valuable for use during pregnancy, when maternal
infection may threaten to spread to the developing fetus. At
present, spiramycin is used for such treatment in Europe, de-
spite the lack of controlled trials showing efficacy (26). Spira-
mycin does not cross the placental barrier and so is not effec-
tive in treating infection in the fetus. Treatment with
pyrimethamine and sulfadiazine (with folic acid supplementa-
tion) is recommended in cases of confirmed fetal infection;
however, this treatment can be given only after the first tri-
mester (26). Pyrimethamine-sulfadiazine treatment has been
shown to improve outcomes in some cases (23); however, it
carries the added risk of adverse drug reactions. Hence, more
effective treatments that have fewer side effects would be ben-
eficial. Artemisone has been shown to be safe in human phase
I trials, and previous studies have shown that it is less neuro-
toxic and antiangiogenic than DHA (8). Despite this improved
safety in humans, artemisone has shown fetal toxicity in a rat
pregnancy model, although rats are more susceptible to these
effects than rabbits (31). Development of less fetotoxic deriv-
atives of artemisinin may be of use for preventing congenital
infections.
We also tested both artemisone and artemiside in a murine
model for reactivation that simulates the situation in immuno-
compromised patients. By treating IFN-/ mice with sulfa-
diazine, it is possible to suppress active replication of
tachyzoites but allow development of tissue cysts (38). Re-
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moval of the drug allows reactivation to occur due to cyst
rupture and spontaneous conversion to tachyzoites. In the ab-
sence of IFN-, this leads to uncontrolled parasite replication
(36). This model mimics the situation with severely immuno-
compromised patients that lack the T cells required to effec-
tively control the parasite. Previous studies have used a very
similar model based on knockout of the interferon consensus
sequence binding protein (ICSBP) to demonstrate the efficacy
of atovaquone for controlling reactivation in the mouse model
of toxoplasmosis (10, 32). In the present study, artemiside
showed slightly better protection in the murine reactivation
model, and mice were also partially protected from lethal re-
activation by treatment with artemisone. This greater potency
might reflect the higher lipophilic nature of artemiside, per-
haps allowing better access to the CNS. Although artemisone
is a relatively polar artemisinin derivative, biodistribution stud-
ies of radiolabeled artemisone in rats indicate moderate pen-
etration of the CNS after oral dosing (35). The corresponding
studies for artemiside have not been carried out, but as it is
substantially more lipophilic than artemisone, blood-brain
penetration is expected to be higher.
The efficacies of artemisone and artemiside compare favor-
ably with that of atovaquone (32), which has been used to
decrease relapse of toxoplasmosis in AIDS patients (7). Combined
treatments with artemisone or artemiside and pyrimethamine or
clindamycin might also prove effective, and such regimens
could provide an alternative for treatment in patients that fail
to tolerate sulfa drugs.
In summary, the potent antimalarial compounds artemisone
and artemiside show reasonable efficacy against toxoplasmosis
in the murine model, raising the possibility that they may also
be effective in controlling human toxoplasmosis.
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